Autoimmune blood tests: what ANA, RF and other markers actually measure

Guides 6 min read
Guides·Dr. Lina HaddadChief Medical Officer·July 17, 2026· 6 min read

Doctors order autoimmune blood tests when symptoms suggest the immune system may be attacking the body's own tissues. Here's what the common markers measure and what a positive result does — and doesn't — mean.

Autoimmune diseases occur when the immune system attacks the body's own tissues. They encompass over 80 conditions — from rheumatoid arthritis and lupus to thyroid disease and type 1 diabetes. Blood tests for autoimmunity look for the antibodies and markers produced during these immune attacks.

Key autoimmune markers

  • ANA (antinuclear antibodies) — a broad screening test; positive in lupus, Sjögren's syndrome, scleroderma and others; also positive in up to 15% of healthy people
  • Anti-dsDNA — more specific for lupus (SLE); used to monitor disease activity
  • RF (rheumatoid factor) — elevated in rheumatoid arthritis but also in other conditions and in healthy older adults
  • Anti-CCP (anti-cyclic citrullinated peptide) — more specific for RA than RF; useful for early diagnosis
  • Anti-TPO (thyroid peroxidase antibodies) — elevated in Hashimoto's thyroiditis and Graves' disease
  • ANCA (antineutrophil cytoplasmic antibodies) — associated with vasculitis; two types (pANCA, cANCA) indicate different conditions
  • Complement levels (C3, C4) — low complement indicates immune complex consumption; seen in active lupus

What a positive result means (and doesn't mean)

A positive autoimmune antibody test is not a diagnosis. Many of these antibodies occur in healthy people, and interpretation requires the full clinical picture — symptoms, examination, other tests and the titre (level) of the antibody. A low-titre positive ANA in an asymptomatic person rarely means anything significant; the same result in someone with joint pain, fatigue and a rash is a very different finding.

These tests are most useful when ordered for specific clinical reasons. Broad 'autoimmune panels' requested without a clinical context frequently generate more anxiety than insight.